These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22393002)

  • 1. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.
    Chapuis AG; Thompson JA; Margolin KA; Rodmyre R; Lai IP; Dowdy K; Farrar EA; Bhatia S; Sabath DE; Cao J; Li Y; Yee C
    Proc Natl Acad Sci U S A; 2012 Mar; 109(12):4592-7. PubMed ID: 22393002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.
    Wang A; Chandran S; Shah SA; Chiu Y; Paria BC; Aghamolla T; Alvarez-Downing MM; Lee CC; Singh S; Li T; Dudley ME; Restifo NP; Rosenberg SA; Kammula US
    Sci Transl Med; 2012 Aug; 4(149):149ra120. PubMed ID: 22932225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.
    Wallen H; Thompson JA; Reilly JZ; Rodmyre RM; Cao J; Yee C
    PLoS One; 2009; 4(3):e4749. PubMed ID: 19270751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.
    Chapuis AG; Roberts IM; Thompson JA; Margolin KA; Bhatia S; Lee SM; Sloan HL; Lai IP; Farrar EA; Wagener F; Shibuya KC; Cao J; Wolchok JD; Greenberg PD; Yee C
    J Clin Oncol; 2016 Nov; 34(31):3787-3795. PubMed ID: 27269940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells.
    Butler MO; Friedlander P; Milstein MI; Mooney MM; Metzler G; Murray AP; Tanaka M; Berezovskaya A; Imataki O; Drury L; Brennan L; Flavin M; Neuberg D; Stevenson K; Lawrence D; Hodi FS; Velazquez EF; Jaklitsch MT; Russell SE; Mihm M; Nadler LM; Hirano N
    Sci Transl Med; 2011 Apr; 3(80):80ra34. PubMed ID: 21525398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.
    Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Dudley ME; Somerville R; Wunderlich JR; Sherry RM; Yang JC; Rosenberg SA; Kammula US
    Clin Cancer Res; 2015 Feb; 21(3):534-43. PubMed ID: 25424856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.
    Chapuis AG; Ragnarsson GB; Nguyen HN; Chaney CN; Pufnock JS; Schmitt TM; Duerkopp N; Roberts IM; Pogosov GL; Ho WY; Ochsenreither S; Wölfl M; Bar M; Radich JP; Yee C; Greenberg PD
    Sci Transl Med; 2013 Feb; 5(174):174ra27. PubMed ID: 23447018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
    Yee C; Thompson JA; Byrd D; Riddell SR; Roche P; Celis E; Greenberg PD
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16168-73. PubMed ID: 12427970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.
    Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Kammula US
    Cancer Res; 2015 Aug; 75(16):3216-26. PubMed ID: 26100671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.
    Powell DJ; Dudley ME; Robbins PF; Rosenberg SA
    Blood; 2005 Jan; 105(1):241-50. PubMed ID: 15345595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
    Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
    J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
    von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
    Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.
    Wu RC; Liu S; Chacon JA; Wu S; Li Y; Sukhumalchandra P; Murray JL; Molldrem JJ; Hwu P; Pircher H; Lizée G; Radvanyi LG
    Clin Cancer Res; 2012 May; 18(9):2465-77. PubMed ID: 22307139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
    Rolle CE; Carrio R; Malek TR
    Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients.
    Meidenbauer N; Marienhagen J; Laumer M; Vogl S; Heymann J; Andreesen R; Mackensen A
    J Immunol; 2003 Feb; 170(4):2161-9. PubMed ID: 12574389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
    Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
    Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors.
    Le Gal FA; Widmer VM; Dutoit V; Rubio-Godoy V; Schrenzel J; Walker PR; Romero PJ; Valmori D; Speiser DE; Dietrich PY
    J Invest Dermatol; 2007 Mar; 127(3):622-9. PubMed ID: 17039243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes.
    Kaka AS; Shaffer DR; Hartmaier R; Leen AM; Lu A; Bear A; Rooney CM; Foster AE
    J Immunother; 2009 Sep; 32(7):726-36. PubMed ID: 19561536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8
    Hasan AN; Selvakumar A; Shabrova E; Liu XR; Afridi F; Heller G; Riviere I; Sadelain M; Dupont B; O'Reilly RJ
    Clin Exp Immunol; 2016 Nov; 186(2):249-265. PubMed ID: 27227483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.